Subependymal giant cell astrocytoma cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Mahshid |
||
(One intermediate revision by one other user not shown) | |||
Line 3: | Line 3: | ||
{{pleasehelp}} | {{pleasehelp}} | ||
== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Line 14: | Line 14: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Neurology]] | |||
[[Category:Neurosurgery]] |
Latest revision as of 17:00, 27 November 2017
Subependymal giant cell astrocytoma Microchapters |
Differentiating Subependymal Giant Cell Astrocytoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Subependymal giant cell astrocytoma cost-effectiveness of therapy On the Web |
American Roentgen Ray Society Images of Subependymal giant cell astrocytoma cost-effectiveness of therapy |
FDA on Subependymal giant cell astrocytoma cost-effectiveness of therapy |
CDC on Subependymal giant cell astrocytoma cost-effectiveness of therapy |
Subependymal giant cell astrocytoma cost-effectiveness of therapy in the news |
Blogs on Subependymal giant cell astrocytoma cost-effectiveness of therapy |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.